Mar 28, 2016 4:05 pm EDT Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences
Mar 23, 2016 9:15 am EDT Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder
Mar 16, 2016 4:45 pm EDT Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting
Mar 03, 2016 4:05 pm EST Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights
Feb 29, 2016 8:00 am EST Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference
Feb 08, 2016 8:00 am EST Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)